Kristin Samuelsson - Publications

Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: June 03, 2026

Plasma cardiac troponin T complements neurofilament light chain by reflecting disease phase and phenotypic variation in amyotrophic lateral sclerosis.

Journal: Journal of neurology

Published: April 22, 2026

Protein Biomarkers in Risk and Prognosis of Amyotrophic Lateral Sclerosis.

Journal: European journal of neurology

Published: December 12, 2025

Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry.

Journal: Journal of internal medicine

Published: September 17, 2025

Novel Clinical Insights From a Swedish RFC1 Spectrum Disorder Cohort.

Journal: European journal of neurology

Published: August 17, 2025

Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.

Journal: European journal of neurology

Published: July 08, 2025

Use of Common Psychiatric Medications and Risk and Prognosis of Amyotrophic Lateral Sclerosis.

Journal: JAMA network open

Published: June 04, 2025

Cutaneous nerve fiber pathology and function in Parkinson's disease and atypical parkinsonism - a cohort study.

Journal: NPJ Parkinson's disease

Published: February 06, 2025

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver.

Journal: International journal of molecular sciences

Published: December 20, 2024

Plasma troponin T reflects lower motor neuron involvement on electromyography in amyotrophic lateral sclerosis.

Journal: Brain communications

Published: December 10, 2024

Association between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: a population-based case-control study.

Journal: The Lancet regional health. Europe

Published: August 19, 2024

Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.

Journal: Pharmacology research & perspectives

Published: March 21, 2024